Ketotifen Hydrogen Fumarate is a specialized pharmaceutical compound with profound implications in the management of allergic conditions. As a white to off-white crystalline powder, it embodies the archetypal pharmaceutical intermediate that serves a critical role in the synthesis of medications aimed at mitigating allergic symptoms. This compound, with the molecular formula C19H19NOS·C4H4O4 and a molecular weight of 425.50 g/mol, is an epitome of pharmacological innovation, designed to alleviate discomfort associated with allergic rhinitis and conjunctivitis, while also playing a preventive role in asthma management. Fabricated with meticulous precision, Ketotifen Hydrogen Fumarate is both soluble in water and ethanol, ensuring versatility in its application for medical formulations. With a melting point between 160-163°C, where it starts decomposing, this substance remains stable under a wide range of conditions, ensuring a dependable shelf-life for pharmaceutical products. When handling this product, adherence to stringent safety guidelines, including the use of personal protective equipment, is imperative to minimize potential contact risks. It demands storage in cool, dry environments, shielded from light and moisture, to preserve its integrity. Respected for its non-sedating nature, Ketotifen distinctively works by inhibiting the discharge of histamine and other mediators from mast cells, thus curtailing the cascade of allergic reactions without inducing significant drowsiness. The side effects are minimal, with mild drowsiness, dry mouth, and nausea being among the most common, while more severe reactions such as confusion or hallucinations are decidedly rare. An advocate for quality and safety, Refarmed Chemicals, a leading pharmaceutical ingredient manufacturer, assures regulatory compliance, with Ketotifen Hydrogen Fumarate approved by the FDA for prescribed use. As such, corporate customers seeking a reliable cornerstone for their allergy-treating formulations will find this product to be a formidable addition to their pharmaceutical repertoire.
Products still subject to third-party patent protection might be available solely for R&D purposes.
